Liverpool University Hospitals NHS Foundation Trust
Liverpool, North West, United Kingdom
NCT Number: NCT06297837
The goal of this study is to improve the way urinary tract infections (UTIs) are tested for antibiotic resistance. The main questions it aims to answer are:
* Can the investigators use a method called Bayesian causal inference to create or check clinical prediction models that help predict if certain antibiotics will work for a urinary infection, using patient information from the National Health Service (NHS)? * Can this new ADAPT-AST method, which uses data and a smarter approach, do a better job of testing for urinary infection than the old methods? Will it help doctors make quicker decisions and save resources by being more efficient?
Participants in this study will not be receiving treatments. The study will involve:
Using statistical methods to predict UTI test results based on patient data. Evaluating whether this new approach can provide doctors with more timely and useful information for treating UTIs.
Assessing whether it can help save money and resources in the lab and pharmacy.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Liverpool, North West, United Kingdom
The aim of this study is to develop and evaluate an adaptive informatics approach for laboratory antimicrobial susceptibility testing (AST) for urinary tract infection (UTI) pathogens compared with current practice to improve patient outcomes, reduce AMR risks and reduce waste of laboratory resources.
UTI is a leading cause of community and hospital acquired infection and a major driver of antimicrobial prescribing in primary and secondary care. The continued proliferation of AMR also increasingly limits treatment choices for many UTIs. Despite the importance of UTI, antimicrobial susceptibility testing (AST) of urine specimens is based on inflexible 'one-size-fits' all standard operating procedures (SOPs). Either a very large unfocused panel of antimicrobials is immediately tested (leading to wasted resources), or more commonly, and particularly in low or middle income (LMIC) settings, a selected subset of antimicrobials is tested at day one prior to a second or even third panel of antimicrobials. Such an approach does not adapt to prior information such as previous resistance patterns, antimicrobial prescribing, or demographic information, despite these factors being powerful (strong) predictors of resistance. This results in imprecise, inefficient, and inequitable provision of antimicrobial susceptibility information, which provides suboptimal support of decisions for treatment of UTI.
This project will use statistical techniques based on Bayesian causal inference to predict urine AST results and prioritise testing using patient demographics, prescribing, admission, and microbiology laboratory care data. The clinical utility of resulting algorithms will be evaluated in terms of their ability to increase the number, timeliness and appropriateness of usable AST results available to clinicians, and their ability to reduce laboratory resource costs through better test prioritisation. The anticipated benefits of a successfully developed, evaluated, and implemented system are faster and more precise treatments of UTI in patients with drug-resistant organisms and more efficient resource management, particularly in laboratory and pharmacy workflows.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
The overall number of susceptible results per panel available at day 1
Time frame: 2 years
The number of susceptible results per panel available for WHO AWaRe Access category agents at day 1
Time frame: 2 years
The number of susceptible results per panel for orally-administrable agents available at day 1
Time frame: 2 years
The number of susceptible results per panel for intravenously-administrable agents available at day 1
Time frame: 2 years
The proportion of panels with no results available for WHO AWaRe Access category agents at day 1
Time frame: 2 years
The proportion of panels with no susceptible results of any kind available at day 1
Time frame: 2 years
The proportion of WHO Access agent susceptible results for the agent with the highest utility value
Time frame: 2 years
The proportion of susceptible results of any kind for the agent with the highest utility value
Liverpool University Hospitals NHS Foundation Trust
Other Gov
Adaptive Prediction of Antimicrobial Susceptibility and Its Implementation to Improve the Management of Urinary Tract Infection
Acronym: ADAPT-AST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04248322
Central Nervous System Diseases, Female Urogenital Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06598514
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Portland, Oregon, United States
View Trial DetailsNCT05826873
Bacterial Infections, Bacterial Infections and Mycoses
St Louis, Missouri, United States
View Trial DetailsNCT03819712
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Nice, France
View Trial Details